Reuters151d agobullish
Lilly stays ahead of the pack as rivals jump on obesity drug bandwagonNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
109last 24h
3129last 7d
511● bullish (7d)
313● bearish (7d)
227publishers
Pharmaceutical Technology152d agoneutral
Novo Nordisk puts AI at the centre of its clinical strategyThe Wall Street Journal153d agoneutral
Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since LaunchThe Wall Street Journal164d agoneutral
Eli Lilly Stock on Track for Record as Insurance Coverage Expands for ZepboundProactive166d agoneutral
Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofAMT Newswires170d agoneutral
European Stocks Close Higher Friday; German Q1 GDP Increases, Semiconductor Shares GainReuters171d agoneutral
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiryMarketWatch173d agoneutral
Some people lose far more weight than others on GLP-1s like Wegovy. Here’s why.